GLP-1s and Pregnancy 2026: Medical Evidence & Safety

Last reviewed: May 29, 2026

Last updated: May 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Current clinical evidence suggests GLP-1 receptor agonists (semaglutide, tirzepatide) should typically be stopped before conception and avoided during pregnancy, though the safety profile continues to evolve as 2026 studies emerge. The FDA classifies most GLP-1s as Category C or has limited pregnancy data, meaning animal studies show risk but human data remains incomplete.

For individuals planning pregnancy or already pregnant, understanding your unique genetic background in glucose and appetite regulation pathways may help you and your provider assess personal risk and timing more thoughtfully. PlexusDx focuses on precision-guided medication decisions—especially important when family planning is on the horizon.

Current FDA Classification and Pregnancy Category Status in 2026

As of 2025–2026, semaglutide and tirzepatide labelling follows the FDA Pregnancy and Lactation Labeling Rule, which replaced the old A/B/C/D/X pregnancy letter categories with narrative risk summaries. Those summaries note that animal reproduction studies showed adverse effects while adequate and well-controlled human studies are lacking, and both labels state the medicine is not recommended during pregnancy. Manufacturers recommend discontinuing GLP-1s before pregnancy.

The American College of Obstetricians and Gynecologists (ACOG) has not issued formal guidance specifically endorsing GLP-1 use in pregnancy, leaving decision-making to individual providers. Most reproductive endocrinologists currently advise stopping GLP-1s at least 2–3 months before attempting conception to allow the medication to clear from your system.

Clinical Evidence: What We Know From Animal and Early Human Studies

Preclinical (animal) studies of GLP-1 agonists showed no structural fetal abnormalities at therapeutic doses. Separately, rodent thyroid C-cell tumours were observed at high doses; that is a carcinogenicity finding rather than a reproductive or developmental one. These findings triggered cautious labeling but do not directly translate to human risk at prescribed doses.

Real-world pregnancy data remains sparse. Post-market pregnancy exposure registries run by the manufacturers are still collecting semaglutide and tirzepatide pregnancy outcomes. A small 2024 observational study in Diabetes Care found no major congenital anomalies in 47 pregnancies exposed to GLP-1s, but sample sizes are too small to rule out rare risks. Larger prospective studies are underway.

Medication Class/Brand	FDA Pregnancy Category	Key Safety Data Gap	Typical Provider Recommendation
Semaglutide (Ozempic, Wegovy)	Category C	Limited human pregnancy studies; animal thyroid effects at high doses	Discontinue 2–3 months before conception
Tirzepatide (Mounjaro, Zepbound)	Category C	Even fewer human data than semaglutide; dual GIP/GLP-1 mechanism untested in pregnancy	Discontinue before conception; highest caution
Retatrutide (experimental)	Preclinical	No human pregnancy data; animal studies ongoing	Not recommended in any pregnancy stage
Insulin (for comparison)	Category B	Extensive safe use in pregnancy; gold standard for diabetes management	Preferred agent for glucose control during pregnancy

Lactation, Breastfeeding, and Infant Exposure

Limited pharmacokinetic data suggests semaglutide and tirzepatide have high molecular weight and may not transfer significantly into breast milk, but manufacturer studies are incomplete. No formal recommendations currently exist for breastfeeding while on GLP-1 therapy, and most providers recommend discontinuing before attempting to conceive or breastfeed.

If weight management or glucose control becomes urgent during the postpartum period, discussing alternatives—such as lifestyle modification, insulin, or conventional diabetes agents with stronger lactation safety data—with your obstetrician or endocrinologist is advisable. Restarting GLP-1s after breastfeeding has ended is an option if medically indicated.

Genetic Predispositions, Metabolic Risk, and Family Planning Decisions

Genetic variants in GIPR and FTO, and MC4R pathways influence how your body responds to appetite signals and glucose homeostasis—information that can contextualize your personal metabolic health and family planning timeline. Knowing whether you carry predispositions toward insulin resistance, impaired glucose regulation, or elevated cardiovascular risk may help you and your reproductive endocrinologist decide when to pause GLP-1 therapy and manage weight through alternative methods.

The Precision Peptide Genetic Test examines key variants (GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that may help clarify your individual metabolic profile. This context allows providers to assess whether GLP-1 continuation carries higher or lower personal relevance during the critical preconception and pregnancy window. Genetic predispositions do not predict medication response exactly, but they can support a more nuanced conversation with your healthcare team.

Provider Decision Framework: When to Stop, When to Restart, and Alternatives

Evidence-based guidance suggests stopping GLP-1s 2–3 months before attempting conception, allowing time for the medication to clear and menstrual cycles to normalize. During pregnancy, insulin and metformin (both Category B) become the standard-of-care options for glucose management if diabetes develops. After delivery and if not breastfeeding, GLP-1s may be restarted once medically indicated.

For individuals with severe obesity, type 2 diabetes, or significant cardiovascular risk who become pregnant while on GLP-1 therapy, providers may weigh the known risks of uncontrolled glucose or continued weight gain against incomplete pregnancy safety data. This is a discussion requiring shared decision-making with your obstetrician, endocrinologist, or maternal-fetal medicine specialist—not a one-size-fits-all recommendation. Lifestyle interventions (nutrition, exercise, behavioral support) remain first-line throughout pregnancy.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that fertility planning and pregnancy decisions are deeply personal. Our Precision Peptide Genetic Test examines predispositions in key metabolic pathways (GIPR, FTO, MC4R variants) that may help provide context about your individual glucose regulation, weight management tendencies, and metabolic risk profile. This information should be interpreted with a qualified healthcare provider to inform timing and medication choices around conception.

Understanding your genetic variants does not predict exactly how you will respond to GLP-1 therapy or what your pregnancy risks will be. Rather, genetic predispositions in peptide pathways can help your provider assess whether GLP-1 continuation is metabolically critical for you during the preconception window, or whether alternative management strategies might be safer and equally effective. This precision approach supports more individualized family planning decisions.

If you are considering pregnancy or already pregnant, PlexusDx recommends consulting your obstetrician and endocrinologist before starting, stopping, or continuing GLP-1 medications. Our genetic test results, combined with your medical history and provider expertise, can support a more informed conversation about the timing of GLP-1 discontinuation, alternative therapies during pregnancy, and when to restart after delivery and lactation.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What do providers generally advise about GLP-1s and trying to conceive?

The article says manufacturers recommend discontinuing GLP-1s before pregnancy, and that most reproductive endocrinologists advise stopping two to three months before attempting conception so the medication can clear. It notes ACOG has not issued formal guidance endorsing GLP-1 use in pregnancy, leaving the decision to individual providers. Timing should be planned with your obstetrician or endocrinologist.

Why is human safety data on GLP-1s in pregnancy still so limited?

The article says real-world pregnancy data remains sparse, with post-market registries still collecting outcomes and existing samples too small to rule out rare risks. Larger prospective studies are described as underway. Animal reproduction findings drove cautious labeling, but the article notes those results do not translate directly to human risk at prescribed doses, which leaves genuine uncertainty.

Which glucose-control options are considered standard during pregnancy?

Insulin, which the article describes as having extensive safe use in pregnancy and calls the preferred agent for glucose control, alongside metformin. It adds that lifestyle interventions covering nutrition, exercise, and behavioral support remain first-line throughout pregnancy. If diabetes develops or worsens while pregnant, those choices are managed by your obstetric and endocrine team.

Is it safe to use a GLP-1 while breastfeeding?

The article says no formal recommendations currently exist for breastfeeding on GLP-1 therapy, and that most providers recommend discontinuing before attempting to conceive or breastfeed. Limited pharmacokinetic data suggests the high molecular weight of these drugs may limit transfer into breast milk, but it notes manufacturer studies are incomplete. Raise this with your obstetrician before deciding.

What happens if someone becomes pregnant while already on a GLP-1?

The article describes it as a shared decision rather than an automatic answer. Providers weigh the known risks of uncontrolled glucose or continued weight gain against incomplete pregnancy safety data, particularly for people with severe obesity, type 2 diabetes, or significant cardiovascular risk. It says that conversation belongs with an obstetrician, endocrinologist, or maternal-fetal medicine specialist, promptly.

Related Reading

• Glp 1S
• Maximus Glp 1
• Found Glp 1
• Orderly Meds Glp 1

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.